Cybin Inc. (CYBN) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Toronto, ON, 캐나다. 현재 CEO는 Eric So.
CYBN 을(를) 보유 IPO 날짜 2019-09-13, 50 명의 정규직 직원, 에 상장 NYSE, 시가총액 $413.02M.
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
